AZN — AstraZeneca Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for AstraZeneca, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	37,417	44,351	45,811	54,073	58,739
Cost of Revenue
Gross Profit	27,875	35,702	37,743	44,415	47,762
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	36,361	40,594	37,618	44,070	44,996
Operating Profit	1,056	3,757	8,193	10,003	13,743
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-265	2,501	6,899	8,691	12,402
Provision for Income Taxes
Net Income After Taxes	115	3,293	5,961	7,041	10,233
Minority Interest
Net Income Before Extraordinary Items
Net Income	112	3,288	5,955	7,035	10,225
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	112	3,288	5,955	7,035	10,225
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.77	3.53	3.41	5.35	6.69
Dividends per Share